Stock Events

Stock Events

Island Pharmaceuticals Limited 

$0.3338
3
+$0.00+0% Wednesday 12:04

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26AugExpected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.01
-0.01
-0.01
-0
Expected EPS
-0.008578196
Actual EPS
-0.008578196

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-2.52MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ILPLF. It's not an investment recommendation.
Apple
2
AAPL
Microsoft
2
MSFT
Tesla
2
TSLA
Amazon
2
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. focuses on the development and marketing of drugs in areas similar to those pursued by Island Pharmaceuticals, including antiviral drugs, which makes them a direct competitor.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that develops vaccines and therapeutic drugs that could compete with Island Pharmaceuticals' antiviral drug development.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products including medicines and vaccines for infectious diseases, directly competing with Island Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson engages in the research and development of pharmaceuticals for infectious diseases, competing in the same space as Island Pharmaceuticals.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. researches and develops pharmaceutical products, including those for viral infections, positioning them as a competitor to Island Pharmaceuticals.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on patented medicines for a range of diseases, including viral infections, which pits them against Island Pharmaceuticals in the pharmaceutical market.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC develops therapies for various infectious diseases, competing with Island Pharmaceuticals in the area of drug development for similar ailments.
Sanofi
SNY
Mkt Cap107.39B
Sanofi operates globally, focusing on pharmaceuticals including vaccines and therapies for infectious diseases, making them a competitor to Island Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb Company offers prescription pharmaceuticals in several therapeutic areas, including virology, which aligns them as competitors with Island Pharmaceuticals.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline plc specializes in the creation and marketing of vaccines and medications for infectious diseases, directly competing with Island Pharmaceuticals in this niche.

About

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Show more...
CEO
Country
Australia
ISIN
AU0000138869
WKN
000A2QSJR

Listings

OTC Link
US
ILPLF
AU
AU
ILA.AU
F
DE
7X0.F

0 Comments

Share your thoughts

FAQ

What is Island Pharmaceuticals Limited stock price today?▼
The current price of ILPLF is $0.33 USD — it has increased by +0% in the past 24 hours. Watch Island Pharmaceuticals Limited stock price performance more closely on the chart.
What is Island Pharmaceuticals Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Island Pharmaceuticals Limited stocks are traded under the ticker ILPLF.
When is the next Island Pharmaceuticals Limited earnings date?▼
Island Pharmaceuticals Limited is going to release the next earnings report on March 03, 2027.
What were Island Pharmaceuticals Limited earnings last quarter?▼
ILPLF earnings for the last quarter are -0.01 USD per share, whereas the estimation was -0.01 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Island Pharmaceuticals Limited revenue for the last year?▼
Island Pharmaceuticals Limited revenue for the last year amounts to 0 USD.
What is Island Pharmaceuticals Limited net income for the last year?▼
ILPLF net income for the last year is -2.52M USD.
In which sector is Island Pharmaceuticals Limited located?▼
Island Pharmaceuticals Limited operates in the Technology sector.
When did Island Pharmaceuticals Limited complete a stock split?▼
Island Pharmaceuticals Limited has not had any recent stock splits.